Attività scientifica e formativa

Ricerca clinica

COLON RETTO

1) A randomized trial investigating the role of FOLFOX-4 regimen duration (3 versus 6 months) and bevacizumab as adjuvant therapy for patients with stage II/III colon cancer. TOSCA. Responsabili: dr.ssa Maria Angela Palladino e Mordenti Patrizia


2) Sequential treatment strategy for metastatic colorectal cancer: a phase iii prospective randomized multicenter study of chemotherapy (ct) with or without bevacizumab as first-line therapy followed by two phase iii randomized studies of ct alone or ct plus bevacizumab with or without cetuximab as second-line therapy. STUDIO IRST 15301-ITACA. Responsabile: dr.ssa Bidin Livia